AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04682028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: coventional care
Description: nurses provide coventional care for the patients.
Study NCT06006091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Different endothelial preparations according to groups, see arm descriptions for details
Study NCT06003608 — intervention group
Intervention type: DEVICE
Intervention: Fluid biopsy capsule
Description: Ingestion of two SIMBA capsules
Study NCT06003608 — intervention group
Intervention type: DRUG
Intervention: Levodopa-Carbidopa Immediate Release
Description: Single dose, Levodopa-Carbidopa Immediate Release
Study NCT05305989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg QD
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study NCT05305989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg BID
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study NCT05305989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 400 mg QD
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study NCT05835115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A deep learning-based myopia and myopic maculopathy detection and prediction system
Description: This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
Study NCT05341518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscapularis repair
Description: To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
Study NCT05102266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1016C
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study NCT05102266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1016D
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study NCT04543513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)
Description: Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
Study NCT04552886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TH-1 Dendritic Cell Immunotherapy
Description: Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
Study NCT06333951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV
Study NCT06333951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered PO
Study NCT04301687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Articular Branch Block
Description: Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
Study NCT04301687 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Block
Description: Subcutaneous injection of 1ml normal sterile saline
Study NCT05974280 — intervention group
Intervention type: DRUG
Intervention: Alofisel
Description: Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
Study NCT05974280 — intervention group
Intervention type: DRUG
Intervention: Fat stem cell
Description: mesenchymal stem cells from adipose (fat) tissue injection
Study NCT06035874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bempedoic acid
Description: Patient willl be randomized 1:1 in both the arms
Study NCT06558123 — intervention group
Intervention type: PROCEDURE
Intervention: block
Description: Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
Study NCT04399941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venography
Description: The venography will be performed as part of the patient's standard of care. The dialysis access will be punctured upstream of the arteriovenous anastomosis in AVF or AVG using a 4-F coaxial access set (Micro- puncture; Cook, Inc, Bloomington, Indiana). The contrast will be injected intravenously by a pump with 200 psi and a bolus of 2m/sec for total of 5 ml during upper extremity vein filming and 10 ml of contrast bolus by 3 ml/s during central vein filming while holding the breath in inspiration in anterioposterior plane.
Study NCT04399941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Description: IVUS will be performed through the same sheath of the coaxial access set using an Eagle Eye Platinum RX digital catheter 7F over a compatible guidewire under fluoroscopic guidance. The lesion will be estimated fluoroscopically from the marker IVUS catheter in the vein and the cranial and caudal margins of stenotic lesion will be directly visualized during pullback of the IVUS catheter.
Study NCT04399941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image processing
Description: Image processing will be performed by two radiologists in a blinded manner on the images devoid of personal identifier. An adjudication committee will oversee the process and confirm their findings in case of a discrepancy.
Study NCT06135792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arginine
Description: See arm description
Study NCT06135792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description
Study NCT05980234 — intervention group
Intervention type: DEVICE
Intervention: Total Hip Arthroplasty with Longevity IT Oblique Liners
Description: Primary or Revision Total Hip Arthroplasty using the Longevity IT Oblique liners according to the approved indications and compatible device.
Study NCT05980234 — intervention group
Intervention type: DEVICE
Intervention: Total Hip Arthroplasty with Longevity IT Offset Liners
Description: Primary or Revision Total Hip Arthroplasty using the Longevity IT Offset liners according to the approved indications and compatible device.
Study NCT06553248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
Study NCT06553248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
Study NCT05217589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funny/Amusing Video Clips
Description: Participants watch 5-7 minutes of video clips that are funny/amusing in nature
Study NCT05217589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horror/Scary Video Clips
Description: Participants watch 5-7 minutes of video clips that are scary in nature
Study NCT05217589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrilling/Suspenseful Video Clips
Description: Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
Study NCT06357169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Glow
Description: two treatments over a one week period. At the first visit they will complete an initial questionnaire regarding current scalp care practices, skin type, and hair type. An initial baseline scalp swab and HairMetrix photography in the two swab sites will be taken at the beginning of this visit. Treatment with the Venus Glow™ device will also occur. To treat, the scalp will be divided into four quadrants. Swab samples will be collected at the first baseline and concurrent treatment session, second treatment session and 3-6 days after the last treatment when participants have returned to their usual cleansing routine.
Study NCT06687343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA Supplement
Description: Dissolved in water and ingested 4 times a day
Study NCT06687343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA Supplement
Description: Dissolved in water and ingested 4 times a day
Study NCT06687343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NEAA Supplement
Description: Dissolved in water and ingested 4 times a day
Study NCT06687343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin Supplement
Description: Dissolved in water and ingested 4 times a day
Study NCT06693583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headsets
Description: Virtual reality (VR) headsets are used as a form of distraction technique widely throughout healthcare. Women will be assisted to apply the VR prior to their colposcopy examination beginning. They will be shown an immersive video of walking through a forest that reminds them to breath deeply. The aim is that this will relax them during the colposcopy examination.
Study NCT06743360 — intervention group
Intervention type: DEVICE
Intervention: Insertion
Description: Twenty orthodontic mini-implants (n=20) (AbsoAnchor SH 1312-08, Dentos, Daegu, South Korea) were randomly chosen (every third screw from a sample of 60) numbered consecutively, and embedded in polivynyl siloxane impression material Variotype heavy putty (Kulzer, Hanau, Germany).
Study NCT06743360 — intervention group
Intervention type: DEVICE
Intervention: Scanning
Description: After the planned movement is achieved, the mini-implant will be removed and provided to laboratory analysis. All screws were sputtered (0.6µm CaCO₄) and scanned in blue-light technology, using a 3D optical scanner (Atos III, Triple Scan, GOM, Germany) to the nearest 2 micrometres. Due to regularly performed calibration procedures, recommended by the manufacturer, an error study was superfluous. Subsequently, the scans were superimposed using GOM Inspect Software (GOM, Braunschweig, Germany) in order to verify the shape and size repeatability.
Study NCT06254651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High resuscitation table
Description: Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
Study NCT06254651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low resuscitation table
Description: Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
Study NCT06746857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Bilateral dorsolateral prefrontal cortex Intermitten Theta Burst Stimulation to
Study NCT06746753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: randomized to receive Angiotensin II continuous infusion for up to 48 hours
Study NCT06746753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: randomized to receive Norepinephrine continuous infusion for up to 48 hours
Study NCT05378178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10381
Description: Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2...) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
Study NCT05889091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRQOL instruments
Description: These instruments include Face Q for Appearance, Eating \& drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
Study NCT05889091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LENT SOMA instrument
Description: LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
Study NCT06479148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista® Aspire™
Description: Eyes will receive enVista® Aspire™ lenses
Study NCT06479148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: An IOL with a slightly extended depth of focus
Description: Eyes will receive lenses with a slightly extended depth of focus
Study NCT06479148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MX60E
Description: Eyes will receive MX60E lenses
Study NCT05726864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELI-002 7P
Description: ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
Study NCT04972201 — intervention group
Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test
Study NCT06482983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation Mode
Description: after intubation different ventilation mode (VC,PC,PC-VG)
Study NCT05432609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Weight bearing CT
Description: Weight bearing CT in loaded and unloaded positions
Study NCT06379100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Intermittent Theta-Burst Transcranial Magnetic Stimulation
Study NCT06379100 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Intermittent Theta-Burst Transcranial Magnetic Stimulation
Study NCT04549454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITSTART+ PBI
Description: Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
Study NCT04549454 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Parenting Advice
Description: General parenting advice
Study NCT05017012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (+) Berahyaluronidase alfa
Description: Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and berahyaluronidase alfa for SC administration.
Study NCT05017012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive pembrolizumab 400 mg IV.
Study NCT05017012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
Study NCT05017012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Study NCT05017012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Study NCT05017012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Study NCT05017012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
Study NCT05017012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
Study NCT06461507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Janda's Approach
Description: For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
Study NCT06461507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Janda's Approach
Description: For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
Study NCT06320743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS ,Ventilation parameters
Description: NIRS ,Ventilation parameters :~Until the patient is taken to the operating table and leaves the operating table routine monitoring parameters, BIS values ,cerebral and peripheral NIRS values, until the patient is intubated and extubated ventilation parameters These parameters; 0. min (before induction), 1. min after induction, pre-post intubation, 5. min, 10. min, 20. min, 30. min, 45. min, 60. min, 90. min after connecting to the ventilator. It will then be noted at 1 hour intervals, and finally at the 5th minute after extubation.
Study NCT06320743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentration
Description: Oxygen concentration :~Alarm limits appropriate to the patient's weight will be determined for all patients, the lower limit of inspired O2 will be set as 30%, the upper limit of inspired CO2 will be set as 5mmHg. If the inspired O2 value drops below 30%, the pulse oximeter peripheral SpO2 drops below 97, and the NIRS values drop by 20%, the oxygen concentration will be increased by 10%
Study NCT03699865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine content
Description: Study-supplied cigarettes will contain either intermediate or very low nicotine content
Study NCT05840380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: instrumental soft tissue mobilization
Description: Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
Study NCT04617171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 MG/ML [Fasenra]
Description: Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
Study NCT04617171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
Study NCT06042504 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS).
Study NCT05509114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
Study NCT05510440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-amino acid derivatives
Description: Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
Study NCT05510440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha-amino acid derivatives
Description: Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
Study NCT05469191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5 STS
Description: For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately.
Study NCT05469191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 10 STS
Description: For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately.